Update on mesenchymal stem cell-based therapy in lupus and scleroderma

Update on mesenchymal stem cell-based therapy in lupus and scleroderma

Current systemic therapies are rarely curative for patients with severe life-threatening forms of autoimmune diseases (ADs). During the past 15 years, autologous hematopoietic stem cell transplantation has been demonstrated to cure some patients with severe AD refractory to all other available thera...

Full description

Bibliographic Details
Main Authors: Cras, Audrey, Farge, Dominique, Carmoi, Thierry, Lataillade, Jean-Jacques, Wang, Dan Dan, Sun, Lingyun
Format: Online
Language:English
Published: BioMed Central 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631077/
id pubmed-4631077
recordtype oai_dc
spelling pubmed-46310772015-11-04 Update on mesenchymal stem cell-based therapy in lupus and scleroderma Cras, Audrey Farge, Dominique Carmoi, Thierry Lataillade, Jean-Jacques Wang, Dan Dan Sun, Lingyun Review Current systemic therapies are rarely curative for patients with severe life-threatening forms of autoimmune diseases (ADs). During the past 15 years, autologous hematopoietic stem cell transplantation has been demonstrated to cure some patients with severe AD refractory to all other available therapies. As a consequence, ADs such as lupus and scleroderma have become an emerging indication for cell therapy. Multipotent mesenchymal stem cells (MSCs), isolated from bone marrow and other sites, display specific immunomodulation and anti-inflammatory properties and appear as ideal tools to treat such diseases. The present update aims at summarizing recent knowledge acquired in the field of MSC-based therapies for lupus and scleroderma. BioMed Central 2015-11-03 2015 /pmc/articles/PMC4631077/ /pubmed/26525582 http://dx.doi.org/10.1186/s13075-015-0819-7 Text en © Cras et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Cras, Audrey
Farge, Dominique
Carmoi, Thierry
Lataillade, Jean-Jacques
Wang, Dan Dan
Sun, Lingyun
spellingShingle Cras, Audrey
Farge, Dominique
Carmoi, Thierry
Lataillade, Jean-Jacques
Wang, Dan Dan
Sun, Lingyun
Update on mesenchymal stem cell-based therapy in lupus and scleroderma
author_facet Cras, Audrey
Farge, Dominique
Carmoi, Thierry
Lataillade, Jean-Jacques
Wang, Dan Dan
Sun, Lingyun
author_sort Cras, Audrey
title Update on mesenchymal stem cell-based therapy in lupus and scleroderma
title_short Update on mesenchymal stem cell-based therapy in lupus and scleroderma
title_full Update on mesenchymal stem cell-based therapy in lupus and scleroderma
title_fullStr Update on mesenchymal stem cell-based therapy in lupus and scleroderma
title_full_unstemmed Update on mesenchymal stem cell-based therapy in lupus and scleroderma
title_sort update on mesenchymal stem cell-based therapy in lupus and scleroderma
description Current systemic therapies are rarely curative for patients with severe life-threatening forms of autoimmune diseases (ADs). During the past 15 years, autologous hematopoietic stem cell transplantation has been demonstrated to cure some patients with severe AD refractory to all other available therapies. As a consequence, ADs such as lupus and scleroderma have become an emerging indication for cell therapy. Multipotent mesenchymal stem cells (MSCs), isolated from bone marrow and other sites, display specific immunomodulation and anti-inflammatory properties and appear as ideal tools to treat such diseases. The present update aims at summarizing recent knowledge acquired in the field of MSC-based therapies for lupus and scleroderma.
publisher BioMed Central
publishDate 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631077/
_version_ 1613496616518418432

Similar Items